Redsense signs collaboration agreement with Physidia to increase patient safety for home hemodialysis patients.
Redsense signs collaboration agreement with home hemodialysis expert
Physidia is the second dialysis monitor manufacturer to include a direct connection to Redsense in accordance with the PAS 63023 standard.
The direct connection enables the dialysis monitor to stop the blood flow automatically when Redsense detects a blood leakage, effectively minimizing the risk of severe blood loss.
“We are working hard to get additional manufacturers to include the PAS 63023 connection in their dialysis machines, and this agreement is an important step forward. It is also inspiring to be able to collaborate with a manufacturer that has a strong focus on the fast-growing home dialysis segment. We are convinced that this growth trend will continue as home dialysis enables a number of benefits for the patient,” says Redsense Medical’s CEO Patrik Byhmer.
“As innovators on the dialysis market focusing on providing the best therapy for the patient, Physidia and Redsense Medical share a similar mindset. We are therefore excited to start up this collaboration, and to be able to provide even greater patient safety by integrating a direct connection to Redsense’s marketleading blood leakage alarm in future versions of our S3 monitor. With the expected growth of the home hemodialysis market, more patients with broader profiles will be enabled to treat at home and our future developments tend to achieve the highest level of ease-of-use and safety for everyone” says Physidia’s CEO Jérôme Augustin.
About Redsense Medical
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage and minimizing blood leakage.
The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.
Redsense Medical AB is listed on Spotlight Stock Market (ticker: REDS).